Current Research
that is ongoing but no longer recruiting

"The important thing is not to stop questioning. Curiosity has its own reason for existing. One cannot help but be in awe when he contemplates the mysteries of eternity, of life, of the marvelous structure of reality. It is enough if one tries merely to comprehend a little of this mystery every day. Never lose a holy curiosity." --- Albert Einstein

We believe that research is needed to improve Diabetes Care and we have a commitment to participation in clinical research projects to advance knowledge of Diabetes. We have participated in research projects, which we feel offer significant benefits to our patients and advance the cause of effective Diabetes care.

=============================================================
GLARGL07496
Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients (TITRATION)
Sponsor: Locemia Solutions ULC


Purpose

The primary objective of this study is to obtain efficacy and safety descriptive data on 2 different titration algorithms: the INSIGHT titration algorithm (self-titration of 1 unit/day) and the EDITION trial algorithm with insulin glargine 300 units/mL when given as basal insulin in uncontrolled type 2 diabetes mellitus (T2DM) patients on basal insulin with or without non-insulin anti-hyperglycemic agent (NIAHA) or in insulin na´ve patients.


=============================================================
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL):

A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes MellituS Sponsor: AstraZeneca Purpose: This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.



=============================================================
MK-8835-002
Sponsor: Merck

Purpose:
To evaluate efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin.



=============================================================
MK-8835-003/B1521022

Purpose To evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of subjects with Type 2 diabetes mellitus and inadequate glycemic control on diet and exercise.



=============================================================
MK 8835-004 (B1521021)

A study of the cardiovascular outcomes following treatment with ertugliflozin in participants with type 2 diabetes mellitus and established vascular disease. The main objective of this study is to assess the cardiovascular safety of ertugliflozin. This trial includes a pre-defined glycemic sub-study in participants receiving background sulfonlyurea monotherapy.

=============================================================
DECLARE-TIMI58
Sponsor: AstraZeneca

Purpose
The main aim of this study being carried out to see if dapagliflozin when added to a patients current anti-diabetes therapy is effective in reducing cardiovascular events such as heart attack, ischemic stroke, and cardiovascular related death, compared with placebo (inactive study medication).



=============================================================
MK-3102-018
Sponsor: Merck

Purpose:
The purpose of this study is to evaluate the cardiovascular (CV) safety profile of MK-3102 in participants with type 2 diabetes mellitus. The primary hypothesis is that treatment with MK-3102 25 mg once weekly is non- inferior to treatment with placebo and active comparators across the MK-3102 program with regard to the risk of developing a confirmed event in the primary CV composite endpoint.


=============================================================
SUSTAIN-6
Sponsor: Novo Nordisk

Purpose:
The aim of this trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes.



=============================================================

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Sponsor: Eli Lilly

Purpose:
The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.



=============================================================

LEADER EX2211-3738
Sponsor: Novo Nordisk

Purpose: to assess the effect of treatment with liraglutide compared to placebo on first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction (MI) or non-fatal stroke in adults at high risk for cardiovascular events.

=============================================================